Table 5.
Hepatocellular carcinoma
| Author | Ions | No. of patients | Tumor diameter (range) (mm) | Dose/fractions | Local control |
Overall survival |
||
|---|---|---|---|---|---|---|---|---|
| 3 years | 5 years | 3 years | 5 years | |||||
| Bush et al. (70), LLUMC | Proton | 34 | 57 (T1–T4) | 63 GyE/15 fr | 75.0% (2 years) | — | 55.0% (2 years) | — |
| Kawashima et al. (71), NCCHE | Proton | 40 | 45 (25–82) | 76 GyE/20 fr | 96.0% (2 years) | — | 66.0% | — |
| Chiba et al. (72), Tsukuba | Proton | 162 | 38 (15–145) | 5–72 GyE/10–24fr | 90.0% | 86.9% | 45.0% | 23.5% |
| Fukumitsu et al. (73), Tsukuba | Proton | 51 | 28 (8–93) | 66 GyE/10 fr | 94.5% | 87.8% | 49.2% | 38.7% |
| Kato et al. (74,75), NIRS | C-ion | 69 | 40 (12–120) | 52.8 GyE/4 fr | 94.0% | 81.0% | 50.0% | 33.0% |
| Imada et al. (76), NIRS | C-ion | 64 | — | Porta hepatis group 52.8 GyE/4 fr | — | 87.8% | — | 22.2% |
| — | Non-porta hepatis group 52.8 GyE/4 fr | 95.7% | 34.8% | |||||
| Imada et al. (77), NIRS | C-ion | 40 | 38 (14–95) | High-dose group: 42.8–45.0 GyE/2 fr | 95.0% | — | 72.0% | — |
| 77 | 45 (15–140) | Low-dose group: 32.0–40.8 GyE/2 fr | 74.0% | — | 54.0% | — | ||